Open AccessImprovement of outcomes in patients with recent acute coronary syndrome: the place of PCSK9 inhibitors. The Resolution of National Advisory Board
Author(s) -
Н. М. Ахмеджанов,
Н. Н. Везикова,
М. И. Воевода,
А. S. Galyavich,
V. S. Gurevich,
D. V. Duplyakov,
M. Ezhov,
Yu. A. Karpov,
В. В. Кашталап,
G A Konovalov,
О. G. Smolenskaya,
A. N. Yakovlev
Publication year - 2019
Publication title -
kardiologiâ
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.159
H-Index - 16
eISSN - 2412-5660
pISSN - 0022-9040
DOI - 10.18087/cardio.n308
Subject(s) - acute coronary syndrome , medicine , pcsk9 , advisory committee , clinical practice , coronary heart disease , ldl cholesterol , intensive care medicine , cholesterol , family medicine , myocardial infarction , political science , lipoprotein , ldl receptor , public administration
On April 9, 2018, the national advisory board “Improvement of outcomes in patients with recent ACS: the place of PCSK9 inhibitors” was held in Moscow. Leading Russian experts in the field of atherosclerosis and lipid-lowering treatment attended the board. The purpose of the Board was to determine the place of PCSK9 inhibitors in the improvement of outcomes in patients with recent (less than 1 year) acute coronary syndrome (ACS). During the Board, three major aspects of lipid-lowering treatment were discussed: 1) issues in reaching the target levels of LDL cholesterol in real clinical practice among patients with recent ACS; 2) the results of ODYSSEY OUTCOMES study and their role in the improvement of outcomes in patients with recent ACS; 3) treatment with PCSK9 inhibitors in the management of patients with recent (less than 1 year) ACS in everyday clinical practice, the role of lipid centers.